Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients

AstraZeneca1,044 enrolled

Overview

The main aim of the study is to describes the outcomes of patients with Upper Gastrointestinal Bleed (UGIB) in a real-life setting. Additionally analyse assessed predictors of outcome, including the impact of hemostatic endoscopic and pharmacologic therapies.

MSD

Study Type

OBSERVATIONAL

Enrollment

1,044

Conditions

Re-bleeding in NVUGIB

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (\>=18yrs) admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia... * Evidence that an upper GI endoscopy was performed Exclusion Criteria: * GI bleeding not from NVUGIB

Locations (3)

Research Site

Da Nang, Vietnam

Research Site

Hanoi, Vietnam

Research Site

HoChiMinh City, Vietnam

Outcomes

Primary Outcomes

Rebleeding (within 7 days from the Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) episode)

Time frame: 7 days

Secondary Outcomes

Surgery due to re-bleeding

Time frame: 7 days

Mortality due to bleeding

Time frame: 7 days

Rebleeding in high risk peptic ulcer patients

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.